Latest Pharma and Biotech News
Biotechnology
10 December 2024 Newly presented data at the American Society of Hematology (ASH) annual meeting highlight significant clinical benefits for Sanofi’s Sarclisa (isatuximab) in multiple myeloma.
Today's issue
Refine Search
Biotechnology
Accent Therapeutics, a targeted cancer drug specialist, has announced the appointment of Serena Silver as chief scientific officer, as current CSO and co-founder Robert Copeland retires. 11 December 2024
Biotechnology
San Diego, USA-based biotech AnaptysBio today announced that investigational ANB032, a BTLA agonist, did not meet the primary and secondary endpoints in any of the doses studied in the global, 201-patient ARISE-AD trial as a monotherapy for moderate-to-severe atopic dermatitis (AD) or eczema. 11 December 2024
Pharmaceutical
Lynparza (olaparib) partners AstraZeneca and Merck & Co have reported updated findings from the Phase III OlympiA trial in breast cancer, showing a sustained survival benefit. 11 December 2024
Biotechnology
Merck KGaA has appointed Miguel Fernández Alcalde as president of its US biopharmaceutical business, EMD Serono. 11 December 2024
Pharmaceutical
Minoryx Therapeutics, a Spanish biotech specializing in therapies for orphan CNS disorders, will submit for European approval for leriglitazone by the middle of next year. 11 December 2024
Pharmaceutical
Swiss specialty pharmaceutical company Santhera Pharmaceuticals has received approval from the National Medical Products Administration in China for Agamree (vamorolone). 11 December 2024
Biotechnology
Shares of US clinical stage biopharma Candel Therapeutics leapt 166% to $12.25 in pre-market activity today, after it announced results from a multicenter Phase III clinical trial evaluating its CAN-2409 viral immunotherapy in localized prostate cancer patients. 11 December 2024
Biotechnology
Indian drugmaker Dr Reddy’s Laboratories has recently become the first Indian company to launch checkpoint inhibitor Zytorvi (toripalimab) in collaboration with Shanghai Junshi Biosciences . 11 December 2024
Biotechnology
US biotech Cardiff Oncology has announced positive initial data from CRDF-004, a randomized, Phase II trial evaluating onvansertib in combination with standard-of-care (SoC) in patients with first-line RAS-mutated metastatic colorectal cancer (mCRC). 11 December 2024
Biotechnology
Netherlands-based Pharming Group today released positive top-line results of data from its Phase III clinical trial (NCT05438407) evaluating the investigational drug leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, in children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS). 11 December 2024
Biotechnology
Noema Pharma, a Swiss biotech targeting debilitating central nervous system (CNS) disorders, has announced the successful close of a Series B extension financing round with an investment from EQT Life Sciences. 11 December 2024
Pharmaceutical
Dutch clinical-stage drug developer NewAmsterdam Pharma saw its shares close up 41% at $26.19 yesterday on positive research results for its cholesterol lower obicetrapib. 11 December 2024
Biotechnology
Boston, USA-based biotech Tasca Therapeutics yesterday announced a $52 million Series A financing, co-led by Regeneron Ventures and Cure Ventures, with participation by Invus Group. 11 December 2024
Biotechnology
Bristol Myers Squibb has presented data on its cell therapy products at the American Society of Hematology (ASH) Annual Meeting and Exposition in San Diego, California. 10 December 2024
Biotechnology
BeiGene has sought to underscore its leading position in the chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) space at the American Society of Hematology (ASH) Annual Meeting and Exposition. 10 December 2024
Biotechnology
Cambridge, USA-based Eikonizo Therapeutics today revealed it has secured an undisclosed equity investment from Novo Nordisk through its Science2Medicine iNNvest initiative. 10 December 2024
Biotechnology
US biotech Nektar Therapeutics has announced results of its Phase II proof-of-concept study of NKTR-255 as an adjuvant treatment to enhance complete response rate (CRR) and durability following CD19-directed CAR-T therapy in patients with relapsed/refractory (R/R) large B-cell lymphoma (LBCL). 10 December 2024
Biotechnology
Dutch gene therapy company uniQure saw its shares rocket 86% to $13.57 today, after it reached agreement with the US Food and Drug Administration (FDA) on key elements of an Accelerated Approval pathway for AMT-130 in Huntington’s disease. 10 December 2024
Biotechnology
Newly presented data at the American Society of Hematology (ASH) annual meeting highlight significant clinical benefits for Sanofi’s Sarclisa (isatuximab) in multiple myeloma. 10 December 2024
Biotechnology
Gilead Sciences has revealed promising five-year data from its Phase II ZUMA-5 trial of Yescarta (axicabtagene ciloleucel), at the American Society of Hematology meeting. 10 December 2024
All news
Biotechnology
US pharma giant Merck & Co today announced positive top-line results from the pivotal Phase III MK-3475A-D77 trial for its mega blockbuster drug Keytruda (pembrolizumab) in subcutaneous form. 19 November 2024
Biotechnology
Aclaris Therapeutics has announced an exclusive licensing agreement with Biosion for broad rights to two new antibodies. 19 November 2024
Biotechnology
Privately-held US biotech Georgiamune has announced the appointment of Mark Avagliano as chief business officer (CBO). 19 November 2024
Biotechnology
Massachusetts, USA-based firm VBI Vaccines has initiated a nationwide voluntary recall of PreHevbrio (hepatitis B vaccine), as it proceeds with bankruptcy and the shutdown of its operations. 19 November 2024
Biotechnology
Australia’s CSL Limited plans to shut down its Californian R&D facility focused on cell and gene therapies by January 2025, signaling a shift away from ex vivo lentiviral-based technology. 19 November 2024
Pharmaceutical
New York-based Mind Medicine, a company developing MM120, a form of LSD (lysergide d-tartrate), for mental health conditions, has announced the appointment of Gregg Pratt, as chief regulatory and quality assurance officer. 19 November 2024
Biotechnology
Germany’s Lindis Biotech, a specialist in multi-specific antibody platforms, has announced an exclusive licensing agreement with Pharmanovia, for the commercialization of Korjuny (catumaxomab). 19 November 2024
Pharmaceutical
UK pharma major GSK today announced positive headline results of GLISTEN, the ongoing global Phase III clinical trial evaluating linerixibat. 19 November 2024
Biotechnology
Cellular immunotherapy specialist Fate Therapeutics soared as much as 73%, and closed up 12.45 at $2.27 yesterday, after it released early-stage data on its FT819 in lupus. 19 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) on Monday approved the medicine Filspari (sparsentan) from Vifor France to treat primary immunoglobulin A nephropathy (IgAN). 19 November 2024
Pharmaceutical
Swiss cancer giant Novartis has entered into an exclusive worldwide licensing and collaboration deal with Ratio Therapeutics, aiming to develop a next-generation radiotherapeutic. 19 November 2024
Pharmaceutical
New York-based ophthalmic technology company Eyenovia is considering its options. 18 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze